Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives
July 24, 2014 7:00 am
While a life-long gluten-free diet (GFD) is effective in most individuals with Celiac disease (CD), it is not effective in some. This could be related to cross contamination of food products, improper/inaccurate labeling and perhaps other factors as well. As a consequence, there is a rationale for the development of medical therapy. A recent study (Gastroenterol 2014; 146: 1649-58) has shown the ability of ALV003, a mixture of 2 recombinant gluten-specific proteases administered orally, to protect patients with celiac disease from gluten-induced mucosal injury in a phase 2 trial.
Methods: In a 6-week challenge study, adults with biopsy-proven celiac disease were divided into a treatment group with ALV003 (n=20) or a placebo group (n=21). The 2.0 g gluten dose (equivalent to 1/2 slice of bread) for the study was determined after an optimization study (using 1.5 g, 3.0 g or 6.0 g of gluten (bread crumbs) in three divided doses). Biopsies were taken before and after the gluten challenge.
Key finding:
Related blog posts:
Posted by gutsandgrowth
Categories: Nutrition, Pediatric Gastroenterology Intestinal Disorder
Tags: ALV003, celiac disease, gluten free diet, gluten threshold
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.